Abstract Background Immune checkpoint inhibitors (ICIs) have dramatically changed the
landscape of cancer treatment. However, only a few patients respond to ICI treatment. Thus …

Background The emergence of immune checkpoint inhibitors (ICIs) is one of the most
promising breakthroughs for the treatment of multiple cancer types, but responses vary …

With the development of technologies, multiple primary lung cancer (MPLC) has been
detected more frequently. Although large-scale genomics studies have made significant …

Objective Chondroblastoma‐like osteosarcoma (CBLOS) is a rare and poorly understood
variant of OS. We examined the clinicopathological, immunohistochemical and molecular …

Colon cancer is the second leading cause of cancer deaths in the United States and on track
to be the leading cause of death in adults younger than 50 years by 2030. 1 First-line …

Abstract Background Pappalysin 2 (PAPPA2) mutation, occurring most frequently in skin
cutaneous melanoma (SKCM) and non‐small cell lung cancer (NSCLC), is found to be …

Background Rare oncogenic driver events, particularly affecting the expression or splicing of
driver genes, are suspected to substantially contribute to the large heterogeneity of …

Simple Summary The recent WHO classification of melanocytic tumors requires the
implementation of combined phenotypic–genotypic diagnostics. For rare tumors, such as …

Lung adenocarcinoma (LUAD) is the most common type of lung cancer. LRP1B was initially
identified as a cancer suppressor in several cancers. However, the potential biological …

Background: Lung adenocarcinoma (LUAD) is the most common type of lung cancer and is
a global public health concern. One-carbon (1C) metabolism plays a crucial role in the …